<DOC>
	<DOC>NCT00582725</DOC>
	<brief_summary>Patients will receive 6 to 8 cycles of R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, and prednisone), with GM-CSF.</brief_summary>
	<brief_title>R-CHOP + GM-CSF for Previously Untreated LCL in Elderly</brief_title>
	<detailed_description>The objective of this study is to estimate complete response rates for patients treated with this regimen, to assess overall response rates, event-free survival and overall survival; and to assess toxicities associated with R-CHOP + GM-CSF. Patients will receive 6 to 8 cycles of R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, and prednisone), with GM-CSF.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<criteria>Histologically confirmed, CD20+ B cell diffuse large cell lymphoma, with measurable or evaluable disease Having no prior chemotherapy, immunotherapy or radiotherapy except for one cycle of CHOP or RCHOP. Pregnant Hepatitis B Surface Antigen positive Have known CNS disease or HIV infection Have NY Classification III or IV disease.</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>DLBCL, Elderly</keyword>
	<keyword>previously untreated DLBCL in the elderly</keyword>
</DOC>